Dr. Qiao transitioned to the role of advisor to Vivace in May 2026. Prior to that, she served as President and CEO and a member of the company’s board of directors from 2015 to 2026. Before co-founding Vivace, she was Managing Director of WuXi Ventures, the corporate venture arm of WuXi AppTec. She was founder of LEAD Therapeutics, Inc, which was acquired by BioMarin in 2010 for its PARP inhibitor in preclinical development (Talazoparib), currently marketed by Pfizer. From 2020 to 2024, she served on the board of directors of Biotechnology Innovation Organization (BIO). She began her industry career as a medicinal chemist at Genzyme Corporation (now part of Sanofi) and worked in management consulting and business development at McKinsey & Company, Syrrx and Discovery Partners International. She received her Ph.D. in organic chemistry from MIT and A.B. in chemistry from Harvard University.